Alcohol pretreatment of stools effect on culturomics.

Actinobacteria / drug effects Adult Aged Bacteria / drug effects Bacteriological Techniques Bacteroidetes / drug effects Clostridioides difficile / drug effects Clostridium Infections / therapy Disinfection Ethanol / pharmacology Fecal Microbiota Transplantation Feces / microbiology Female Firmicutes / drug effects Gastrointestinal Microbiome Humans Male Proteobacteria / drug effects Species Specificity Specimen Handling / methods Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Spores, Bacterial / drug effects Succinates / metabolism

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 03 2020
Historique:
received: 10 04 2019
accepted: 02 03 2020
entrez: 7 4 2020
pubmed: 7 4 2020
medline: 26 11 2020
Statut: epublish

Résumé

Recent studies have used ethanol stool disinfection as a mean of promoting valuable species' cultivation in bacteriotherapy trials for Clostridium difficile infections (CDI) treatment with a particular focus on sporulating bacteria. Moreover, the culturomic approach has considerably enriched the repertoire of cultivable organisms in the human gut in recent years. This study aimed to apply this culturomic approach on fecal donor samples treated with ethanol disinfection to evidence potential beneficial microbes that could be used in bacteriotherapy trials for the treatment of CDI. Thereby, a total of 254 bacterial species were identified, 9 of which were novel. Of these, 242 have never been included in clinical trials for the treatment of CDIs, representing potential new candidates for bacteriotherapy trials. While non-sporulating species were nevertheless more affected by the ethanol pretreatment than sporulating species, the ethanol disinfection technique did not specifically select bacteria able to sporulate, as suggested by previous studies. Furthermore, some bacteria previously considered as potential candidates for bacteriotherapy have been lost after ethanol treatment. This study, while enriching the bacterial repertoire of the human intestine, would nevertheless require determining the exact contribution of each of species composing the bacterial consortia intended to be administered for CDI treatment.

Identifiants

DOI: 10.1038/s41598-020-62068-x PMID: 32251347 PMC: PMC7089995
pubmed: 32251347
doi: 10.1038/s41598-020-62068-x
pii: 10.1038/s41598-020-62068-x
pmc: PMC7089995
doi:

Substances chimiques

Succinates 0
Ethanol 3K9958V90M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5190

Références

Pépin, J. et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can. 171, 466–472 (2004).
doi: 10.1503/cmaj.1041104
McDonald, L. C. et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433–2441 (2005).
doi: 10.1056/NEJMoa051590 pubmed: 16322603 pmcid: 16322603
Loo, V. G. et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442–2449 (2005).
doi: 10.1056/NEJMoa051639 pubmed: 16322602 pmcid: 16322602
Lessa, F. C. et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825–834 (2015).
doi: 10.1056/NEJMoa1408913 pubmed: 25714160 pmcid: 25714160
Khoruts, A., Dicksved, J., Jansson, J. K. & Sadowsky, M. J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44, 354–360 (2010).
pubmed: 20048681 pmcid: 20048681
Lewis, B. B. et al. Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. J. Infect. Dis. 212, 1656–1665 (2015).
doi: 10.1093/infdis/jiv256 pubmed: 25920320 pmcid: 25920320
Ferreyra, J. A. et al. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16, 770–777 (2014).
doi: 10.1016/j.chom.2014.11.003 pubmed: 25498344 pmcid: 25498344
Gens, K. D., Elshaboury, R. H. & Holt, J. S. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J. Pharm. Pract. 26, 498–505 (2013).
doi: 10.1177/0897190013499527 pubmed: 23966282 pmcid: 23966282
Gerding, D. N. et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719–1727 (2015).
doi: 10.1001/jama.2015.3725 pubmed: 25942722 pmcid: 25942722
Dieterle, M. G., Rao, K. & Young, V. B. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann. N. Y. Acad. Sci. 1435, 110–138 (2019).
doi: 10.1111/nyas.13958 pubmed: 30238983 pmcid: 30238983
Hamilton, M. J., Weingarden, A. R., Sadowsky, M. J. & Khoruts, A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107, 761–767 (2012).
doi: 10.1038/ajg.2011.482 pubmed: 22290405 pmcid: 22290405
van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
doi: 10.1056/NEJMoa1205037 pubmed: 23323867 pmcid: 23323867
Brandt, L. J. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am. J. Gastroenterol. 108, 177–185 (2013).
doi: 10.1038/ajg.2012.450 pubmed: 23318479 pmcid: 23318479
Goldenberg, S. D. et al. Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infect. Dis. Ther. 7, 71–86 (2018).
doi: 10.1007/s40121-018-0189-y pubmed: 29450831 pmcid: 29450831
Zipursky, J. S., Sidorsky, T. I., Freedman, C. A., Sidorsky, M. N. & Kirkland, K. B. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 55, 1652–1658 (2012).
doi: 10.1093/cid/cis809
Petrof, E. O. et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1, 3 (2013).
doi: 10.1186/2049-2618-1-3 pubmed: 24467987 pmcid: 24467987
Tvede, M., Tinggaard, M. & Helms, M. Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 21, 48–53 (2015).
Khanna, S. et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. J. Infect. Dis. 214, 173–181 (2016).
doi: 10.1093/infdis/jiv766 pubmed: 26908752 pmcid: 26908752
Tvede, M. & Rask-Madsen, J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet Lond. Engl. 1, 1156–1160 (1989).
doi: 10.1016/S0140-6736(89)92749-9
Emanuelsson, F., Claesson, B. E. B., Ljungström, L., Tvede, M. & Ung, K.-A. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand. J. Infect. Dis. 46, 89–97 (2014).
doi: 10.3109/00365548.2013.858181 pubmed: 24354958 pmcid: 24354958
Koransky, J. R., Allen, S. D. & Dowell, V. R. Use of ethanol for selective isolation of sporeforming microorganisms. Appl. Environ. Microbiol. 35, 762–765 (1978).
doi: 10.1128/AEM.35.4.762-765.1978 pubmed: 348108 pmcid: 348108
Lagier, J.-C. et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 18, 1185–1193 (2012).
Lagier, J.-C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 16203 (2016).
doi: 10.1038/nmicrobiol.2016.203 pubmed: 27819657 pmcid: 27819657
Barker, A. K. et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J. Antimicrob. Chemother. 72, 3177–3180 (2017).
doi: 10.1093/jac/dkx254 pubmed: 28961980 pmcid: 28961980
Tojo, R. et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J. Gastroenterol. 20, 15163–15176 (2014).
doi: 10.3748/wjg.v20.i41.15163 pubmed: 25386066 pmcid: 25386066
Ruiz, L., Delgado, S., Ruas-Madiedo, P., Sánchez, B. & Margolles, A. Bifidobacteria and Their Molecular Communication with the Immune System. Front. Microbiol. 8, 2345 (2017).
doi: 10.3389/fmicb.2017.02345 pubmed: 29255450 pmcid: 29255450
Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).
doi: 10.1038/s41571-018-0006-2 pubmed: 29636538 pmcid: 29636538
Wu, F. et al. Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. Exp. Ther. Med. 14, 3122–3126 (2017).
doi: 10.3892/etm.2017.4878 pubmed: 28912861 pmcid: 28912861
Ishaq, H. M. et al. Molecular Alteration Analysis of Human Gut Microbial Composition in Graves’ disease Patients. Int. J. Biol. Sci. 14, 1558–1570 (2018).
doi: 10.7150/ijbs.24151 pubmed: 30263008 pmcid: 30263008
Wilson, B. C., Vatanen, T., Cutfield, W. S. & O’Sullivan, J. M. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front. Cell. Infect. Microbiol. 9 (2019).
Van der Meulen, R., Adriany, T., Verbrugghe, K. & De Vuyst, L. Kinetic analysis of bifidobacterial metabolism reveals a minor role for succinic acid in the regeneration of NAD+ through its growth-associated production. Appl. Environ. Microbiol. 72, 5204–5210 (2006).
doi: 10.1128/AEM.00146-06 pubmed: 16885266 pmcid: 16885266
Fischbach, M. A. & Sonnenburg, J. L. Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe 10, 336–347 (2011).
doi: 10.1016/j.chom.2011.10.002 pubmed: 22018234 pmcid: 22018234
Rios-Covian, D. et al. Interactions between Bifidobacterium and Bacteroides Species in Cofermentations Are Affected by Carbon Sources, Including Exopolysaccharides Produced by Bifidobacteria. Appl. Env. Microbiol. 79, 7518–7524 (2013).
doi: 10.1128/AEM.02545-13
Morotomi, M., Nagai, F., Sakon, H. & Tanaka, R. Dialister succinatiphilus sp. nov. and Barnesiella intestinihominis sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 58, 2716–2720 (2008).
doi: 10.1099/ijs.0.2008/000810-0 pubmed: 19060046 pmcid: 19060046
Del Dot, T., Osawa, R. & Stackebrandt, E. Phascolarctobacterium faecium gen. nov, spec. nov., a Novel Taxon of the Sporomusa Group of Bacteria. Syst. Appl. Microbiol. 16, 380–384 (1993).
doi: 10.1016/S0723-2020(11)80269-9
De Vadder, F. et al. Microbiota-Produced Succinate Improves Glucose Homeostasis via Intestinal Gluconeogenesis. Cell Metab. 24, 151–157 (2016).
doi: 10.1016/j.cmet.2016.06.013 pubmed: 27411015 pmcid: 27411015
La transplantation de microbiote fécal et son encadrement dans les essais cliniques - Point d’Information - ANSM: Agence nationale de sécurité du médicament et des produits de santé. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/La-transplantation-de-microbiote-fecal-et-son-encadrement-dans-les-essais-cliniques-Point-d-Information2.
Lagier, J.-C. et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 34, 1597–1601 (2015).
doi: 10.1007/s10096-015-2394-x
Duncan, S. H., Hold, G. L., Harmsen, H. J. M., Stewart, C. S. & Flint, H. J. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int. J. Syst. Evol. Microbiol. 52, 2141–2146 (2002).
pubmed: 12508881 pmcid: 12508881
Browne, H. P. et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533, 543–546 (2016).
doi: 10.1038/nature17645 pubmed: 27144353 pmcid: 27144353
Seng, P. et al. Ongoing Revolution in Bacteriology: Routine Identification of Bacteria by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. Clin. Infect. Dis. 49, 543–551 (2009).
doi: 10.1086/600885 pubmed: 19583519 pmcid: 19583519
Dubourg, G. et al. The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 32, 637–645 (2013).
doi: 10.1007/s10096-012-1787-3
Stackebrandt, E. & Ebers, J. Taxonomic parameters revisited: Tarnished gold standards. Microbiol. Today 8, 6–9 (2006).
Kim, M., Oh, H.-S., Park, S.-C. & Chun, J. Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. Int. J. Syst. Evol. Microbiol. 64, 346–351 (2014).
doi: 10.1099/ijs.0.059774-0 pubmed: 24505072 pmcid: 24505072

Auteurs

Pamela Afouda (P)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Marie Hocquart (M)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Thi-Phuong-Thao Pham (TP)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Edmond Kuete (E)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Issa Isaac Ngom (II)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Niokhor Dione (N)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Camille Valles (C)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Sara Bellali (S)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Jean-Christophe Lagier (JC)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Grégory Dubourg (G)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Didier Raoult (D)

Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France. didier.raoult@gmail.com.
IHU Méditerranée Infection, Marseille, France. didier.raoult@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes irréguliers à Gram positif › Actinobacteria › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Bactéries › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Techniques microbiologiques › Techniques bactériologiques › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Bactéries › Bactéries à Gram négatif › Bacteroidetes › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Bactéries › Firmicutes › Clostridiales › Clostridioides › Clostridium difficile › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Clostridium › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Contrôle des maladies transmissibles › Prévention des infections › Stérilisation › Désinfection › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Composés chimiques organiques › Alcools › Éthanol › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Thérapeutique › Biothérapie › Transplantation de microbiote fécal › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Liquides et sécrétions biologiques › Fèces › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Bactéries › Firmicutes › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Microbiome gastro-intestinal › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Bactéries › Proteobacteria › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Phénomènes biologiques › Spécificité d'espèce › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Manipulation d'échantillons › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Spectrométrie de masse › Spectrométrie de masse MALDI › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Stades d'organismes › Spores › Spores bactériens › Alcohol pretreatment of stools effect on culturomics.
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Diacides carboxyliques › Succinates › Alcohol pretreatment of stools effect on culturomics.